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Regenerative medicineCell-based therapies for regeneration of intervertebral discs are regarded to hold promise for
degenerative disc disease treatment, a condition that is strongly linked to lower back pain. A de novo
self-assembling peptide hydrogel (SAPH), chosen for its biocompatibility, tailorable properties and
nanofibrous architecture, was investigated as a cell carrier and scaffold for nucleus pulposus (NP) tissue
engineering. Oscillatory rheology determined that the system would likely be deliverable via minimally
invasive procedure and mechanical properties could be optimised to match the stiffness of the native
human NP. After three-dimensional culture of NP cells (NPCs) in the SAPH, upregulation of NP-specific
genes (KRT8, KRT18, FOXF1) confirmed that the system could restore the NP phenotype following de-
differentiation during monolayer culture. Cell viability was high throughout culture whilst, similarly to
NPCs in vivo, the viable cell population remained stable. Finally, the SAPH stimulated time-dependent
increases in aggrecan and type II collagen deposition, two important NP extracellular matrix components.
Results supported the hypothesis that the SAPH could be used as a cell delivery system and scaffold for
the treatment of degenerative disc disease.
Statement of Significance
Lower back pain (LBP) prevalence is widespread due to an aging population and the limited efficacy of
current treatments. As LBP is strongly associated with intervertebral disc (IVD) degeneration, it is thought
that cell-based therapies could alleviate LBP by repairing IVD tissue.
Various natural and synthetic biomaterials have been investigated as potential IVD tissue engineering
scaffolds. Self-assembling peptide hydrogels (SAPHs) combine advantages of both natural and synthetic
biomaterials; for example they are biocompatible and have easily modifiable properties.
The present study demonstrated that a de novo SAPH had comparable strength to the native tissue,
was injectable, restored the IVD cell phenotype and stimulated deposition of appropriate matrix compo-
nents. Results illustrated the promise of SAPHs as scaffolds for IVD tissue engineering.
Crown Copyright  2016 Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Lower back pain (LBP) affects as much as 84% of people in their
lifetime [1] with the cost to the UK economy estimated at £12billion per annum [2]. LBP aetiology is multi-factorial, with
genetics [3], mechanical injury [4] and aging all contributing to
the condition. However intervertebral disc (IVD) degeneration, also
known as degenerative disc disease (DDD), is strongly associated
with LBP in over 40% of cases [5].
The IVD consists of 3 distinct but interdependent tissues; the
fibrous annulus fibrosus (AF) which surrounds the gelatinous
nucleus pulposus (NP) [6] with cartilage end-plates on the superior
and inferior surfaces [7]. The main roles of the IVD are to act as a
shock absorbing system by transferring loads and dissipating
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DDD occurs when there is an imbalance between IVD extracellular
matrix (ECM) catabolic and anabolic events [10] which often leads
to an inflammatory reaction [11].
Current LBP treatments have limited long-term efficacy [12]
and crucially are symptomatic rather than curative. LBP prevalence
is rising due to an aging population [13] so there is an urgent need
for an entirely new approach DDD treatment.
DDD originates within the NP [14] therefore it has been hypoth-
esised that restoration of a degenerated NP when a healthy AF is
present may slow DDD, provide analgesic effects and restore
mobility of the back [7] whilst still preserving the capacity of the
IVD to remodel [15,16]. A number of animal model trials that
investigated the transplantation of NP cells (NPCs) into artificially
degenerated IVDs have produced promising results [17] with
increases in ECM production and maintenance of disc height
reported [18–20]. Injection of autologous human IVD derived
chondrocytes into the NPs of LBP sufferers determined that, after
a 2 year follow-up, cell therapy provided superior analgesic effects
and higher fluid levels than the control population [21].
Due to the disadvantages of current biomaterials, such as lack of
biocompatibility and issues with matching the biomechanics of
native tissue [22,23], self-assembling peptide hydrogels (SAPHs)
have been investigated as potential NP tissue engineering cell car-
riers and scaffolds. SAPHs have the inherent ability to self-
assemble into complex supramolecular structures after exposure
to the appropriate stimuli [24,25]. The simple self-assembly mech-
anism produces hydrogels suitable for the culture of a number of
cell lines [22,26,27]. In theory, SAPHs combine the advantages of
natural and synthetic biomaterials whilst overcoming their defi-
ciencies [23,28]. For example, the peptide sequence can be easily
modified to control the final mechanical and structural properties
[22] whilst SAPHs are likely to display good biocompatibility as
their breakdown products will be the same as those of proteins
synthesised in vivo.
A number of SAPH classes have been investigated for applica-
tions in NP tissue engineering with promising biocompatibility
results reported however these studies did not investigate the rhe-
ological behaviour of the SAPHs despite the important biomechan-
ical role of the NP [29–31]. Furthermore, these (and similar) NP
SAPH studies used a limited and non-NP specific set of marker
genes [29–32] therefore the phenotype of the encapsulated cells
could not be confirmed. We have previously identified a number
of novel genes that characterize the bovine IVD transcriptional pro-
files, allowing determination of a NPC phenotype [33].
FEFEFKFK (F; phenylalanine, E; glutamic acid, L; lysine) chains
have a hydrophobic and hydrophilic face [24,27] so an increase
in solution ionic strength and pH causes the chains to self-
assemble into anti-parallel b-sheets nanofibres. Above a critical
gelation concentration, the nanofibres aggregate into a self-
supporting hydrogel accompanied by a significant increase in vis-
cosity and slight reduction in volume [22]. FEFEFKFK SAPHs have
been successfully exploited as drug delivery vehicles [34] and cell
culture scaffolds [27,35]. Bovine articular chondrocytes encapsu-
lated within FEFEFKFK SAPH adopted rounded morphology, prolif-
erated and produced the cartilage ECM component type II collagen
which suggested that cells retained their phenotype. It was con-
cluded that the system was a suitable bovine chondrocyte cultureTable 1
Constituents required to produce 25, 30 and 35 mg ml1 FEFEFKFK SAPHs.
Final SAPH concentration/mg ml1 Peptide powder/mg dH2O/ll
25 31.25 811
30 37.5 802
35 43.75 786environment and could serve as a template for cartilage tissue
engineering [36]. Previous studies have highlighted a strong simi-
larity in cell morphology and ECM production between chondro-
cytes and NPCs [33,37]. We postulated that the FEFEFKFK SAPH
should therefore be capable of supporting NPC culture, preserving
their phenotype and stimulating production of appropriate ECM
components.
In this study, FEFEFKFK SAPH was investigated for its potential
as a cell carrier and scaffold for NP tissue engineering. The system
was characterised then optimised to match the native NP strength
and to determine its injectability. Finally, the 3D culture of primary
bovine NPCs was analysed for cell viability, gene expression of
encapsulated cells and production of ECM components to deter-
mine whether the FEFEFKFK SAPH could restore and preserve the
NP phenotype.
2. Materials & methods
2.1. Preparation of SAPH
Table 1 describes the FEFEFKFK SAPH production process where
the predetermined amount of peptide powder (>95% purity, batch
LR294429) (Biomatik, USA) was dissolved in distilled water (dH2O).
The samples (pH 1.9–2.1) were heated at 80 C for 2 h to ensure
complete dissolution. The gelation process was induced by the
addition of 1 M NaOH and 100 ll of 10 Dulbecco’s phosphate buf-
fered solution (DPBS) (HyClone, USA). Further heating at 80 C for
12 h aided mixing of constituents. Cooling to room temperature
(RT) produced a homogenous clear hydrogel with a pH of between
9.3 and 9.6.
2.2. Oscillatory rheology to determine viscoelastic properties
Viscoelastic behaviour was determined using an AR-G2
rheometer with 20 mm parallel plates on days 1, 7 and 14 after
plating FEFEFKFK SAPH (Section 2.4). For each run, 150 ll of sam-
ple was loaded onto the stage and the upper plate was lowered to a
0.25 mm gap. A strain amplitude sweep was performed at constant
frequency (1 Hz) between 0.01 and 100% strain to determine the
linear viscoelastic region of the material. The storage modulus
(G0), the deformation energy stored during the shear process of
the sample [38], and loss modulus (G00), the amount of energy dis-
sipated during shear [24], was recorded at 1% strain (frequency
sweep). A recovery cycle experiment on day 1, designed to mimic
the injection process, involved breaking the SAPH by applying
160% strain then reducing the strain to 1% and recording G0 and
G00 values. All samples were tested at 37 C and a solvent trap
was used to minimise solvent evaporation.
2.3. Bovine NPC isolation and culture
Bovine NPCs (bNPCs) were isolated from bovine tails (18–
36 months) purchased from a local abattoir. Each sample was
enzymatically digested in serum-free media containing 0.5% pro-
nase (Merck Chemicals Ltd, Nottingham, UK) for one hour and trans-
ferred to serum free media containing 0.5% collagenase type II
(Invitrogen, Paisley, UK) and 0.1% hyaluronidase (Sigma, Poole, UK)
for two to three hours on an orbital shaker at 37 C. Supernatant1M NaOH/ll 10 DPBS/ll Cell suspension or medium/ll
89 100 250
98 100 250
114 100 250
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BNPCs were expanded under standard culture conditions in high
glucose Dulbecco’s Modified Eagle’s medium (PAA, Austria) supple-
mented with 10% (v/v) foetal bovine serum (FBS), 1% (v/v) peni-
cillin and 1% (v/v) streptomycin (Sigma-Aldrich, USA). At 80%–90%
confluence, cells were sub-cultured using 0.05% trypsin–0.53 mM
ethylenediaminetetraacetic acid (EDTA)4Na solution (Gibco–Invit-
rogen, UK) and transferred to a Falcon tube to recover the cell pellet
by centrifugation. The cell pellet was re-suspended in fresh med-
ium, cells were counted and volume adjusted to the required cell
concentration.
2.4. 3D seeding of FEFEFKFK SAPHs
FEFEFKFK SAPHs were sterilised for 30 min using ultra violet
(UV) radiation. 250 ll of cell suspension containing either
2.5  105 bNPC ml1 or 1.875  106 bNPCs ml1 at passage 4–6
was mixed with the FEFEFKFK SAPH ensuring a homogenous distri-
bution of cells so the final cell density was either 2  105 -
bNPCs ml1 or 1.5  106 bNPCs ml1 of FEFEFKFK SAPH. For
acellular samples used in rheology experiments, 250 ll of medium
was added to FEFEFKFK SAPHs instead of cell suspension. The pre-
determined peptide powder amounts in Table 1 have been
adjusted so that addition of 250 ll cell suspension produced the
final desired FEFEFKFK SAPH concentration. 450 ll of sample was
pipetted into a 12-well Millicell cell culture insert (Millipore,
UK) then fresh media was added. Samples were then incubated
at 37 C (20% O2, 5% CO2). Every 25 min for a total of 125 min,
the cell culture media was changed to return the FEFEFKFK SAPHs
to a physiologically relevant pH. Media was subsequently
exchanged every 2 days and samples were cultured under standard
conditions.
2.5. Cell viability
Cell viability was assessed using LIVE/DEAD assay (Invitrogen,
UK) on days 1, 3, 7 and 14 after cell encapsulation. Samples were
incubated in PBS supplemented with 10 mM calcein AM and
1 mM ethidium homodimer-1 for 15 min at 37 C. The solution
was removed and samples were imaged using a Leica TCS SP5 con-
focal microscope (Leica Microsystems, Germany) and LASAF soft-
ware. 200 lm stacks were imaged at 5 lm intervals along the
axial plane and 500 lm stacks were imaged at 5 lm intervals along
the sagittal plane.
2.6. Total viable cell numbers (CytoTox 96 cytotoxicity assay)
Viable cell numbers were determined using CytoTox 96 cyto-
toxicity assay (Promega, UK) on days 1, 3, 7 and 14 after cell encap-
sulation. Cells in FEFEFKFK SAPH were lysed using a freeze-thaw
process then 50 ll of supernatant was mixed with 50 ll of sub-
strate assay mix. Samples were covered and incubated for 30 min
at RT. Stop solution was added then absorbance was measured
on an Ascent microplate reader at 492 nm wavelength. A standard
curve was produced using known cell numbers then total viable
cells was calculated.
2.7. DNA quantitation assay (Quant-iTTM Picogreen dsDNA assay)
PicoGreen reagent was prepared using a 1:200 dilution with
TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) and protected
from light. A DNA standard curve (0.1–1000 ng ml1) was prepared
using known DNA concentrations.
A lysis buffer step was not required as the encapsulated cells
had been papain digested (in preparation for BlyscanTM GAG assay
Section 2.10). In triplicate, 100 ll of sample, blank and DNAstandard dilutions were pipetted into a black 96-well plate.
100 ll of PicoGreen working solution was then added into each
well and mixed. Samples were incubated at RT for 4 min and pro-
tected from light. The plate was analysed on an FLx800 microplate
reader (BioTEK, USA) with the fluorescence being measured using
filters with a 485 nm excitation and a 538 nm emission wave-
length. A standard curve was plotted using known cell number
against fluorescence.
2.8. Determining gene expression
On days 1, 7 and 14 after cell encapsulation, the entire SAPH
sample was transferred to a microcentrifuge tube and 1 ml of
TRIzol reagent (Life Technologies, UK) was added. The sample
was mechanically disrupted and incubated for 15 min. RNA
was isolated from bNPCs according to the manufacturer’s
instructions and quantified using a NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies, USA). cDNA was prepared
using the ABI high capacity kit (Applied Biosystems, USA) and
diluted to 5 ng ll1.
Quantitative real time polymerase chain reaction (qRT-PCR)
was performed to analyse gene expression using the Applied
Biosystems StepOne PlusTM real-time PCR system. Reactions were
prepared in triplicate to a total volume of 20 ll containing SYBR
Green mastermix (Thermo Fisher Scientific, USA), molecular grade
H2O, 600 nM of each primer [33] and 10 ng of cDNA. Primer
sequences are provided in Table 2. Target gene expression was nor-
malised to GAPDH and expressed as 2DCT.
2.9. Visualisation of extracellular matrix components
Immunocytochemistry (ICC) was used to stain for aggrecan, and
collagen I and II on days 3 and 7 after cell encapsulation. Samples
were fixed with 4% (w/v) paraformaldehyde (PFA) for 30 min at RT.
Then bNPCs were permeabilised using 0.05% (v/v) Triton X-100 in
PBS for 15 min and blocked with 1% (w/v) bovine albumin serum
(BSA) in PBS for 1 h. Samples were incubated overnight at 4 C with
the appropriate primary antibody; rabbit polyclonal to collagen
type I (ab34710), rabbit polyclonal to collagen type II (ab34712)
(Abcam, UK) or mouse monoclonal to aggrecan (7D4) (AbD Serotec,
USA) at a dilution of 1:100, 1:200 and 1:500 respectively. Samples
were then incubated for 90 min at RT in the dark using secondary
goat anti-rabbit IgG-AlexaFluor 594 (1:500 dilution in BSA)
(Thermo Fisher Scientific, USA) for type I and II collagen samples
and secondary goat anti-mouse IgG AlexaFluor 568 (1:500 dilu-
tion) (Thermo Fisher Scientific, USA) for aggrecan samples. Alexa-
Fluor 488 phalloidin (1:150 dilution) stained for F-actin. Between
each step, samples were washed 5 times with DPBS. Samples were
cured using DAPI-ProLong anti-fade and imaged using Leica TCS
SP5 confocal microscope and LASAF software.
2.10. Quantification of total sulphated glycosaminoglycans
Total sulphated glycosaminoglycans (s-GAG) content was mea-
sured using BlyscanTM Glycosaminoglycan Assay (Biocolor, UK)
which utilised 1, 9-dimethyl methylene blue (DMMB) to bind to
s-GAGs. FEFEFKFK SAPHs were papain digested overnight at
65 C on days 1, 3, 7 and 14 after cell encapsulation, then dye
reagent was added to the samples and mechanically mixed for
30 min. After centrifuging, the bound pellet was dissociated and
the s-GAG was recovered using a dissociation agent containing
sodium dodecyl sulphate. Absorbance was measured using a
Multiskan plate reader at 656 nM. Quant-iT PicoGreen assay
(Invitrogen, USA) (Section 2.7) was carried out on the same sam-
ples to determine cell number and s-GAG production per cell
was calculated.
Table 2
Quantitative RT-PCR primer sequences.
Gene Forward primers (50-30) Reverse primers (50-30)
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) TGCCGCCTGGAGAAA CC CGCCTGCTTCACCACC TT
Aggrecan (ACAN) GGGAGGAGACGACTG
CAATC
CCCATTCCGTCTTGTTT
TCTG
Type I collagen (COL1A2) CTGTTCTGTTCCTTGTGTAACTGTGTT GCCCCGGTGACACATCAA
Type II collagen (COL2A1) CGGGCTGAGGGCAACA CGTCAGCCATCCTTCAGA
Transcription factor SOX9 (SOX9) GGGAAGCCTCACATCGACTTC GGACATTACCTCATGGCTGATCT
Keratin 8 (KRT8) ACCAGGAGCTCATGAATGTCAA TCGCCCTCCAGCAGCTT
Keratin 18 (KRT18) AAGGCCAGCTTGGAGAACAG TTGAGCTGCTCCATCTGCAT
Forkhead Box F1 (FOXF1) TCCCTCCCCACCTCAGAAGT TGGCTTCAGAAATGCAAGTTACTC
Carbonic anhydrase 12 (CA12) CCAACAACGGCCACTCAGT CCCCGGACCTGCATGTC
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sulphate (CS/DS)
1.5  106 bNPCs ml1 were seeded into 30 mg ml1 FEFEFKFK
SAPHs as described in Section 2.4. After 5 days, media containing
50 lCi/ml of [3H]-glucosamine (PerkinElmer, USA) was added to 3
separate FEFEFKFK SAPHs to generate metabolically radiolabelled
GAGs as used previously [39]. On day 7 (48 h after [3H]-
glucosamine addition), the entire SAPH and cell culture media
was transferred to a falcon tube, and the final volume adjusted to
20 ml with 1 PBS. Samples were digested with 200 lg/ml pronase
for 4 h at 37 C, and vortexed periodically to aid digestion of the
SAPH. GAG chains were isolated by anion-exchange chromatogra-
phy. In brief, samples were loaded onto a 1 ml diethy-
laminoethanol (DEAE) (Sigma-Aldrich, USA) column, washed with
0.25 M NaCl to remove weakly bound contaminants, and bound
GAGs eluted with 1.5 M NaCl, monitoring for radiolabel using a
Wallac 1409 liquid scintillation counter (PerkinElmer, USA). Eluted
GAGs were pooled and de-salted using a PD-10 disposable Sepha-
dex G-25M size exclusion column (GE Healthcare, UK) eluted in
dH2O, and lyophilised. For CS/DS disaccharide compositional anal-
ysis, recovered GAGs were digested with 2 mU chondroitinase ABC
(AMSBio, UK) using 2 mU enzyme in 500 ll 50 mM Tris, 50 mM
NaCl (pH 7.9) over 12 h and separated from non-digested GAG
using size exclusion chromatography (Superdex 30, Fischer Scien-
tific, UK); radioactivity was monitored as above. The eluted CS/DS
disaccharides were then pooled and lyophilised. An aliquot
(10,000 cpm of 3H) of CS/DS disaccharides was applied to a Hyper-
sil 5 lm column (Thermo Scientific, USA) and analysed by SAX-
HPLC. Disaccharides were eluted with a 45 min linear gradient of
0–0.7 M NaCl in HPLC-grade water (pH 3.5) at a flow rate of
1 ml/minute. Fractions of 0.5 ml were collected and analysed by
scintillation counting. Disaccharides were identified by compar-
ison of elution position with known standards (Iduron, UK). The rel-
ative contribution of each disaccharide was expressed as a
percentage of the total counts.
2.12. Preparation and seeding of alginate hydrogels
Alginate gels were used as positive controls for cell viability and
cell population experiments on days 1 and 7 after encapsulation.
The 2  105 bNPCs were re-suspended in 450 ll 30 mg ml1 algi-
nate solution (Fisher Scientific, UK). The homogenous suspension
was added to a cell culture insert surrounded by 100 mM CaCl2
solution (Sigma-Aldrich, USA) where gelation occurred. After
10 min, CaCl2 was removed, gels were washed with 0.9% NaCl solu-
tion then fresh media was added to the samples which were cul-
tured under standard conditions.
2.13. Statistical analysis
Statistical analysis was performed using one-way ANOVA to
determine significant statistical differences between data. All datawas expressed as mean ± standard deviation (SD) apart from gene
expression results where data was expressed as mean ± standard
error (SE). A significant P value is indicative of a significant differ-
ence where the probability is less than 0.05 (*P < 0.05), 0.01
(**P < 0.01) and 0.001 (***P < 0.001).3. Results
3.1. Characterising and optimising FEFEFKFK SAPH mechanical
properties
Oscillatory rheology determined that for acellular FEFEFKFK
SAPHs at 10 Hz, 25 mg ml1 had G0 value of 6.4 ± 0.3 kPa,
30 mg ml1 had G0 value of 19.6 ± 6.7 kPa and 35 mg ml1 had
G0 value of 51.1 ± 9.5 kPa on day 1 (Fig. 1A). For cell laden
FEFEFKFK SAPHs at 10 Hz, 25 mg ml1 had G0 value of
8 ± 0.4 kPa, 30 mg ml1 had G0 value of 21.4 ± 2.9 kPa and
35 mg ml1 had G0 value of 41.1 ± 8.6 kPa on day 1. There were
no significant differences in G0 values on day 1 for cell-laden
and cell-free FEFEFKFK SAPHs at 30 mg ml1 and 35 mgml1
concentrations (Fig. 1A). All concentrations experienced signifi-
cant decreases in G0 values with increasing time point for
example at 1 Hz, G0 was 16.9 ± 1.8 kPa on day 1 compared to
4.3 ± 1.8 kPa on day 14 for 30 mg ml1 concentration. However,
G0 remained around 2–8 times higher than G00 for all samples
due to FEFEFKFK SAPH always exhibiting predominantly elastic
behaviour (G0 > G00) (Fig. 1B).
The dynamic modulus (|G⁄|) represents the total resistance of
the material to deformation when repeatedly sheared and is
analogous to stiffness. The |G⁄| value for acellular and cell-
laden 30 mg ml1 FEFEFKFK SAPH over a range of 1–100 rad s1
was not significantly different to native non-degenerate NPs as
measured by Iatridis et al. (Fig. 1C) [8]. 25 mg ml1 FEFEFKFK
SAPHs displayed comparable stiffness to the native NP of
5.39 kPa measured by Cloyd et al. [7]. The phase angle (d) indi-
cates energy dissipation during shearing. At 10 rad s1, the d
value of the native NP was 24o which indicated that it was
visco-elastic with a dominant elastic component but still dis-
played a high viscous component [8]. At the same frequency
on day 1, the d value of 7.2 ± 0.9 for cell-laden FEFEFKFK SAPH
meant that the system was less viscous and more elastic than
the native NP.
3.2. Recovery cycles
The recovery cycle (Fig. 2A) was designed to simulate the injec-
tion process; the sample was sheared by applying a 160% strain to
replicate the FEFEFKFK SAPH being forced through a needle
(G0 < G00). A 1000 ll pipette tip (inner diameter of 0.78 mm) was
typically used to plate samples whilst a 19G needle (inner diame-
ter of 0.69 mm) was also used. When the strain was reduced to 1%,
G0 > G00 within 6 s and the FEFEFKFK SAPH recovered its original
Fig. 1. Mechanical properties of acellular and cell-laden FEFEFKFK SAPH and comparison of system to native human NP. [A] Frequency sweep data for acellular and cell-laden
25, 30 and 35 mg ml1 FEFEFKFK SAPH on day 1. [B] Frequency sweep data for 2  105 bNPCs ml1 in 30 mg ml1 FEFEFKFK SAPH on days 1, 7 and 14. [C] Dynamic modulus
comparison of the native NP (red) as determined by Iatridis et al., acellular 30 mg ml1 FEFEFKFK SAPH (black) and 30 mg ml1 FEFEFKFK SAPH with 2  105 bNPCs ml1
(purple). SAPHs at pH 7.4. FEFEFKFK SAPH values expressed as mean ± SD where n = 3. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 2. Injectability of FEFEFKFK SAPH. [A] Recovery cycles for 2  105 bNPCs ml1 in 30 mg ml1 FEFEFKFK SAPHs at pH 7.4 after 1 day of in vitro culture. [B] Cell numbers
calculated using CytoTox 96 non-radioactive cytotoxicity assay for 30 mg ml1 FEFEFKFK SAPHs with 2  105 bNPCs ml1. There was no significant difference between cell
population after 1 day of in vitro cell culture and after cells had been subjected to recovery cycles (P > 0.05). Values expressed as mean ± SD where n = 3.
S. Wan et al. / Acta Biomaterialia 46 (2016) 29–40 33stiffness within a few minutes. The ability of the FEFEFKFK SAPH to
shear thin followed by self-heal was repeatable at least twice on
the same sample. There was no significant difference in cell num-
bers on day 1 for samples subjected to 3 recovery cycles in compar-
ison to control samples that did not undergo recovery cycles
(Fig. 2B).3.3. Assessing cell viability
There was a majority of viable bNPCs present for 25, 30 and
35 mg ml1 FEFEFKFK SAPH concentrations at all time points
(Fig. 3A). The proportion of viable cells present in fluorescence
micrographs was 68.2 ± 4.1% for 25 mg ml1, 80 ± 6.4% for
34 S. Wan et al. / Acta Biomaterialia 46 (2016) 29–4030 mgml1 and was 73.7 ± 1.7% for 35 mg ml1 on day 7
(Fig. 3B). Accordingly, 30 mg ml1 concentration was chosen to
continue with cell culture experiments where there was no sig-
nificant difference in percentage viable cells comparing day 1–14
(Fig. 3C).Fig. 3. Bovine NPC viability in FEFEFKFK SAPH. [A] LIVE/DEAD assay for cell viability of 2
30 mg ml1 alginate gels on days 1 and 7. Viable cells were stained green and dead cells w
LIVE/DEAD assay fluorescence micrographs for 25 mg ml1, 30 mg ml1 and 35 mg ml
mean ± SD where n = 3. [C] Percentage viable bNPCs present in LIVE/DEAD assay fluoresc
culture experiments, over 14 day culture. (*P < 0.05). Values expressed as mean ± SD w
FEFEFKFK SAPH and 30 mg ml1 alginate gel. Values expressed as mean ± SD where n =
referred to the web version of this article.)No significant changes in viable cell population were detected
from days 1 (5.8  105 bNPCs) to 7 (4.6  105 bNPCs). There were
no significant differences in cell number at any time point when
comparing the culture of bNPCs in FEFEFKFK SAPHs and alginate
controls (Fig. 3D). 105 bNPCs ml1 in 25 mg ml1, 30 mg ml1 and 35 mg ml1 FEFEFKFK SAPHs and
ere stained red. Scale bar represents 100 lm. [B] Percentage viable bNPCs present in
1 FEFEFKFK SAPHs on days 1 and 7. (*P < 0.05, ***P < 0.001) Values expressed as
ence micrographs for 30 mg ml1 FEFEFKFK SAPHs, the concentration chosen for cell
here n = 3. [D] Total viable cell population for 2  105 bNPCs ml1 in 30 mg ml1
4. (For interpretation of the references to colour in this figure legend, the reader is
S. Wan et al. / Acta Biomaterialia 46 (2016) 29–40 353.4. Determining cell gene expression using conventional and NP-
specific markers
Following culture of bNPCs in FEFEFKFK SAPH, expression of
the conventional NP markers COL2A1 and SOX9, and novel NP-
specific markers KRT8, KRT18 and FOXF1 significantly increasedFig. 4. [A] Gene expression for conventional NP markers (COL1A2, ACAN, SOX9, COL2A1
30 mg ml1 FEFEFKFK SAPHs on days 1, 7 and 14. Gene expression was normalised
2  105 bNPCs ml1 in 30 mg ml1 FEFEFKFK SAPH. White arrows highlight extracellular
actin was stained green and cell nuclei were stained blue. Scale bar represents 100 lm. [
type II collagen and aggrecan was stained red, F-actin was stained green and cell nuclei w
colour in this figure legend, the reader is referred to the web version of this article.)from days 1–14 (***P < 0.001) (Fig. 4A). COL1A2 gene expression
remained consistently low; around 45 times lower than
COL2A1 and 130 times lower than ACAN on day 14. The ratio
of ACAN to COL2A1 expression was 3:1 on day 14. Expression
of CA12 was not significantly influenced by culture time in
FEFEFKFK SAPH.) and NP-specific markers (KRT8, KRT18, FOXF1, CA12) for 1.5  106 bNPCs ml1 in
to GAPDH. (***P < 0.001). Values expressed as mean ± SE where n = 4. [B] ICC for
matrix deposition. Type I collagen, type II collagen and aggrecan were stained red, F-
C] ICC for 2  105 bNPCs ml1 on glass monolayer culture on day 7. Type I collagen,
ere stained blue. Scale bar represents 100 lm. (For interpretation of the references to
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Minimal type I collagen staining was observed on day 3 and day
7 when bNPCs were cultured in FEFEFKFK SAPHs (Fig. 4B). There
was intense pericellular staining for type II collagen and aggrecan
on day 7 for bNPCs cultured in FEFEFKFK SAPHs. Objectively, there
was a time-dependent increase in amounts of type II collagen and
aggrecan staining.
In contrast, bNPCs cultured on glass adopted a fibroblastic mor-
phology (Fig. 4C). There was intense staining for type I collagen,
minimal staining for type II collagen and no positive aggrecan
staining.
3.6. Quantification of s-GAG
There was a significant increase in total s-GAG accumulation
from days 1 (0.71 ± 0.06 lg) to 14 (1.72 ± 0.8 lg) (**P < 0.01)
(Fig. 5A). When total s-GAG accumulation per day was normalised
with viable cell number in the sample, there was a significant
increase in s-GAG production per cell from day 1 (8.4  103 ±
1.9  104 ng) to 14 (0.033 ± 0.017 ng) (*P < 0.05) (Fig. 5B). No
s-GAG was detected in pooled media which suggested that the
majority of s-GAG was retained by the FEFEFKFK SAPH.Fig. 5. Quantification of ECM components. [A] Total s-GAG accumulation in samples f
calculated from a standard graph plotting absorbance against standard s-GAG concen
Normalised s-GAG production per cell at a seeding density of 1.5  106 bNPC ml1 in 30
viable cell number on corresponding time point to estimate s-GAG production per c
disaccharide composition of 1.5  106 bNPCs ml1 in 30 mg ml1 FEFEFKFK SAPHs on day
expressed as mean ± SD. Sample A, n = 4 HPLC runs; Sample B n = 2 HPLC runs; Sample3.7. Compositional analysis of CS/DS
Metabolic radiolabel incorporation followed by targeted enzy-
matic digestion was used to focus on the specific contribution of
CS and DS to the total GAG deposited by bNPCs during culture.
Digestion generates an unsaturated uronic acid therefore the
iduronic/glucuronic acid ratio could not be calculated using this
method. CS/DS chain composition was not significantly different
between samples (Fig. 5C). The overall GAG composition was
approximately 45.9 ± 8.8% DUA-GalNAc(4S), (A unit), 42.7 ± 9.6%
DUA-GalNAc(6S), (C unit), 9.3 ± 2.1% DUA-GalNAc (O unit) and
2.15 ± 0.42% DUA-GalNAc(4, 6S)/DUA-(2S)GalNAc(6S) (D and E
units). There was no significant difference in ratio of A unit to C
unit with the ratio approximately 1 to 1.
4. Discussion
In this study, the potential of FEFEFKFK SAPH as a cell delivery
system and scaffold for NP tissue engineering was investigated.
There are a number of important parameters to consider for poten-
tial NP biomaterial scaffolds including comparable mechanical
properties to the native tissue, the ability of the system to be
delivered via minimally invasive procedure, biocompatibility,or 1.5  106 bNPC ml1 in 30 mg ml1 FEFEFKFK SAPHs. s-GAG accumulation was
trations. (**P < 0.01, ***P < 0.001). Values expressed as mean ± SD where n = 4. [B]
mg ml1 FEFEFKFK SAPHs. The total accumulated s-GAG in samples was divided by
ell. (*P < 0.05, **P < 0.01). Values expressed as mean ± SD where n = 4. [C] CS/DS
7. CS/DS was extracted from 3 individual FEFEFKFK SAPHs containing bNPCs. Values
C n = 2 HPLC runs.
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of appropriate ECM production.
Oscillatory rheology determined that FEFEFKFK SAPH concen-
tration was proportional to system stiffness (Fig. 1A) as an increase
in fibre density caused more fibre associations and entanglements
[25,36]. All concentrations of acellular and cell-laden FEFEFKFK
SAPHs experienced reductions in G0 and G00 with increasing time-
point (Fig. 1B) likely caused by degradation of the system due to
the very high water content and its relative weakness. Cells are
also likely to have produced various factors and enzymes that
reduced the stability of the scaffold [40]. Reducing FEFEFKFK SAPH
degradation i.e. by changing the peptide chain charge would be a
worthwhile investigation to improve the stability of the system
over long term culture. The NP has a crucial mechanical role [9]
therefore it was important to try and match the biomechanical
properties of FEFEFKFK SAPH to that of the native tissue. The native
human NP modulus, ranging from 5.39 kPa [7] to 20 kPa [8], could
be replicated by varying the FEFEFKFK SAPH concentration
(Fig. 1A). Systems with insufficient mechanical properties are
likely to fail after implantation whilst the transfer of loads to the
AF might be ineffective. Systems that are too rigid could prevent
pericellular remodelling which is crucial for the health of cells
[40] and could accelerate DDD. The d value of the FEFEFKFK SAPH
was a better match to the native NP than other NP tissue engineer-
ing studies, for example Chen et al. HA-gelatin hydrogel had d val-
ues of between 0 to 3o meaning that was dominant elastic with
little viscous properties [41]. IVD surgery can accelerate DDD
[42,43] therefore a cell-based therapy should be deliverable via
minimally invasive implantation [7,42] to minimise damage to
the AF and to fill irregularly shaped defects [44]. After shearing,
the FEFEFKFK SAPH behaved more like a liquid (G00 > G0) however
became more solid-like (G0 > G00) [38] within 6 s. This suggested
that the system could be injectable as it flowed when submitted
to shear stress i.e. through a small bore needle, then recovered
its original stiffness when the shear stress was removed. A number
of other studies on FEFEFKFK SAPH [36] and similar SAPHs [46]
support the hypothesis that shear-thinning and self-healing sys-
tems are injectable. The FEFEFKFK SAPH shear thinning mechanism
has not been extensively investigated, but as demonstrated by b-
hairpin SAPHs, it could involve the nanofibre network fracturing
to allow flow of material [45] with the self-healing mechanism
caused by domains immediately percolating after removal of strain
[45,46]. Shear thinning and self-healing systems do not rely on
external stimuli to trigger the sol-gel transition [34] therefore
should reduce leakage from the site of implantation [45]. The
recovery cycles did not have a significant adverse effect on cell
numbers (Fig. 2B) as NPCs are exposed to high hydrostatic and
osmotic pressures in the native tissue [8,47]. This is in agreement
with previous studies where the injection process had little impact
on cell viability or distribution [45].
Biocompatibility of FEFEFKFK SAPH was assessed and it was
determined that 30 mg ml1 concentration supported the highest
NPC viability (Fig. 3A & B) possibly due to system stiffness being
most comparable to the native NP, placing cells in the most biome-
chanically appropriate microenvironment (Fig. 1A). High cell via-
bility over in vitro culture, as demonstrated in Fig. 3C, is a
requirement for NP tissue engineering strategies. Similar viability
results demonstrating no significant differences between time
points were recorded for the culture of rabbit NPCs in LN-NS SAPH
(89% on day 7) [30] and human NPCs in RAD-RAK SAPH (86% on
day 7) [31]. The characteristic NPC rounded morphology [48] was
maintained in FEFEFKFK SAPHs (Fig. 3A), comparable to NPCs in
the native tissue [49] and was a distinct morphologic alteration
from the fibroblast-like morphology of monolayer culture. Viability
and morphology were similar to other NP tissue engineering stud-
ies using a variety of biomaterial scaffolds [50–52] and for bNPCscultured in alginate controls (Fig. 3A & D). Alginate controls dis-
played a significant time-dependent loss of stability therefore
day 14 data was not available.
NPCs will only significantly proliferate when under stress
[53], when cultured in monolayer [54] or during DDD [55] which
leads to decreased type II collagen and aggrecan production and
increased type I collagen production [56]. Crucially ECM deposi-
tion is also decreased when cells are in the proliferative state
[51,57]. The main goal of the FEFEFKFK SAPH was to stimulate
appropriate ECM production for tissue regeneration [30] and to
regulate cell behaviour [58]. Therefore the stable viable cell
population (Fig. 3D) was not of particular concern as NPCs were
behaving, in terms of proliferation, as they would in the native
tissue. Interestingly, most published papers investigating the
culture of NPCs in SAPHs did not carry out cell number quantifi-
cation assays [29–31]. There was an initial drop in viable cell
numbers during seeding and plating the FEFEFKFK SAPH due to
the basic nature of the culture environment likely inducing pH
shock for some bNPCs. However after the pH levels were
returned to more physiologically relevant levels following media
washes (Section 2.4), no significant amounts of cell death
occurred which suggested that the FEFEFKFK SAPH at pH 7.4
was a suitable culture environment.
NPCs lose their phenotypic characteristics during monolayer
culture as COL2A1and ACAN expression is downregulated [54]
whilst COL1A2 expression increases [59]. Therefore it is crucial that
NP tissue engineering scaffolds are able to re-differentiate NPCs.
The significant gene expression increases with culture period of
conventional NP markers SOX9 and COL2A1 and the NP-specific
markers KRT8, KRT18 and FOXF1 strongly suggested that FEFEFKFK
SAPH could restore and preserve the NP phenotype throughout
in vitro culture (Fig. 4A). Only one previous NP tissue engineering
study has used as extensive a panel of NP markers; Kim et al.
detected time-dependent significant increases in KRT8 and KRT18
gene expression [48] after the culture of bNPCs in HA hydrogels.
The ACAN to COL2A1 expression ratio from freshly harvested NPCs
cultured in monolayer has been reported at 1:1 [60]. However in
the native NP, the aggrecan to type II collagen ratio at the protein
level has been reported as 27:1 [61]. Deposition of aggrecan and
type II collagen are closely related to the cellular corresponding
gene expression levels [30,62]. On day 14, the ACAN to COL2A1 ratio
for this study was higher in comparison to the culture of NPCs in
HA gels after 28 days [48] or LN-NS SAPH after 14 days [30] where
both studies reported a ratio of around 1:1. This suggested that a
more gelatinous matrix was being produced by NPCs cultured in
FEFEFKFK SAPHs.
ICC determined that NPCs cultured in FEFEFKFK SAPH deposited
the vital NP ECM components of type II collagen and aggrecan
extracellularly (Fig. 4B). Type I collagen, which is produced by
NPCs from degenerated IVDs [59], was not significantly produced
(Fig. 4B). In contrast, monolayer culture stimulated NPCs to
produce type I collagen with no significant type II collagen or
aggrecan deposition (Fig. 4C). It was evident from ICC micrographs
that to ensure phenotypic stability of NPCs and production of NP
associated ECM components, three-dimensional culture in an
appropriate scaffold was essential [63].
Quantitative measurement of s-GAGs from PGs, with aggrecan
the most prevalent in the NP, demonstrated a significant time-
dependent increase in s-GAG accumulation and normalised NPC
s-GAG production (Fig. 5A & B). Results supported our hypothesis
that stable viable NPC population was not of major concern as
appropriate ECM deposition could take place in absence of cellular
proliferation. Significant increases in normalised s-GAG to DNA
ratios were reported for NPCs cultured in HA hydrogels [48],
alginate [64] and KLD-12 SAPHs (from days 1–7) [29] with these
studies reporting significantly higher s-GAG accumulation that
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cell-seeding densities used by the comparable studies ranging from
4  106 cells ml1 [64] to 60  106 cells ml1 [48]. Increasing cell
seeding density has been demonstrated to directly correlate with
an increase in s-GAG accumulation [65]. No s-GAG was detected
in the pooled media which suggested that the FEFEFKFK SAPH
was effective in retaining synthesised PGs. Bringing together the
ACAN gene expression results with the increasing levels of total
s-GAG, it was likely that there was an increase in aggrecan deposi-
tion by the bNPCs during culture in the SAPH and this may also
have been the case for other ECM components. A number of NP tis-
sue engineering studies demonstrated time-dependent increases
in ACAN and COL2A1 expression accompanied by increasing corre-
sponding protein deposition [48,59]. Therefore it was likely that
the higher ACAN to COL2A1 expression ratio (Fig. 4A) meant that
more aggrecan than type II collagen was deposited at the protein
level, however a type II collagen quantification assay would be
required to confirm this hypothesis. ICC (Fig. 4B) and s-GAG quan-
tification assays (Fig. 5A & B) demonstrated that NP-associated
ECM components were deposited by bNPCs over the culture period
however due to the low cell-seeding density and length of study it
was unlikely that the matrix contributed to overall SAPH integrity
as demonstrated by the decrease in mechanical properties over
culture period (Fig. 1B).
Aggrecan consists of keratan sulphate chains, and CS/DS chains
enriched in UA-GalNAc(4S) A unit and UA-GalNAc(6S) C unit type
disaccharides [66]. UA-GalNAc(6S) was found to be the most
prevalent s-GAG disaccharide in bovine NPs [67] however our
study demonstrated that there was no significant difference
between A and C unit contribution after culture of bNPCs in
FEFEFKFK SAPHs (Fig. 5C). Quantification of GAG production by
NPCs in potential tissue engineering scaffolds has not been exten-
sively investigated, however Horner et al. determined that there
was intense ICC staining extracellularly for both A unit and C unit
by bNPCs cultured in alginate gels [68] and Maldonado et al. deter-
mined that the GAG composition for canine NPCs in alginate beads
was 31% A unit, 61% C unit and 8% E unit [69]. Both UA-GalNAc(4S)
and UA-GalNAc(6S) are present in human NP ECM in varying
amounts dependent on age. At 1–4 years old, the ratio between
UA-GalNAc(4S) and UA-GalNAc(6S) is around 2:1 with UA-
GalNAc(4S) becoming dominant at older ages [70]. CS/DS levels
and sulphation patterning is tissue-specific [71], linked to PG func-
tion and strongly influenced by the microenvironment therefore
monitoring of CS/DS profiles of encapsulated cells and comparison
with those of the native NP is a useful additional measure of likely
therapeutic use.
Transplantation of NPCs into degenerated NPs has produced
promising results with regards to the treatment of DDD and LBP
[17,21]. Our research first focused on optimisation and characteri-
sation of FEFEFKFK SAPH then NPC culture was investigated, as the
application of FEFEFKFK SAPH for NP tissue engineering was previ-
ously untested. We hypothesised that the nanofibrous architecture
[25] and optimised mechanical properties of the FEFEFKFK SAPH
mimicked the native NP ECM. The culture environment directed
NPCs to re-differentiate and preserve their phenotype after encap-
sulation as evidenced by upregulation of recently identified NP-
specific genes and stimulated production of crucial NP-associated
ECM components which were detected by a wide range of analyt-
ical techniques. Data suggested that FEFEFKFK SAPH could be used
to deliver NPCs into degenerate NPs where transplanted cells
would restore native ECM for the treatment of DDD and LBP. This
study acted as crucial background work for progression of research
towards the culture of human mesenchymal stem cells (MSCs),
currently regarded to be one of the most promising NP tissue
engineering cell sources [12], in FEFEFKFK SAPH. It was essential
to study the response of NPCs in the system as ultimatelydifferentiation of MSCs to a NP-like phenotype is required. Further
characterisation of the system will be needed to determine the
effect of scaffold properties (such as pH and stiffness) on MSCs
and to promote their differentiation towards the NP-like
phenotype.5. Conclusion
Presented results supported the hypothesis that FEFEFKFK SAPH
could be used as a NPC carrier and scaffold for NP tissue engineer-
ing. Characterisation and optimisation of the FEFEFKFK SAPH
demonstrated that the native NP strength could be closely repli-
cated and the system displayed shear-thinning and self-healing
properties which indicated that it was likely deliverable via a
minimally invasive procedure. From a cell biology standpoint,
upregulation of NP-specific genes confirmed that the system
restored the NP phenotype following monolayer culture de-
differentiation and the discogenic phenotype was preserved
throughout in vitro culture. High NPC viability was supported for
the duration of experiments and NPCs were stimulated into
depositing NP-associated ECM components. We hypothesised
that the comparable mechanical properties of the FEFEFKFK SAPH
to the native NP as well as the nanofibrous architecture of the
systemmimicked the native ECM and provided a suitable microen-
vironment for NPCs and thus suggests that the system holds
potential as a cell-based therapy for NP tissue engineering and is
fully deserving of further investigation.Acknowledgements
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